帕博利珠单抗联合阿昔替尼对比舒尼替尼一线治疗晚期肾细胞癌:KEYNOTE-426扩展随访
KEYNOTE-426是一项随机、开放标签、3期研究,纳入861例未经治疗的晚期透明细胞肾细胞癌患者,按1:1随机接受帕博利珠单抗联合阿昔替尼或舒尼替尼单药治疗。
要点
- 联合组治疗相关3级及以上高血压22%、ALT升高13%、腹泻11%。
核心结论
- 扩展随访显示帕博利珠单抗联合阿昔替尼较舒尼替尼持续具有更优的临床结局。
- 结果继续支持帕博利珠单抗联合阿昔替尼作为晚期肾细胞癌一线标准治疗。
研究设计与样本
- 正在进行的随机、开放标签、3期KEYNOTE-426研究,纳入129个中心、16个国家的成人患者。
- 入组未经治疗、晚期透明细胞肾细胞癌患者861例,按1:1随机分组。
- 帕博利珠单抗200 mg静脉每3周最多35周期联合阿昔替尼5 mg口服每日两次,或舒尼替尼50 mg口服每日一次用4周休2周。
- 随机按IMDC风险状态和地理区域分层,主要终点为意向治疗人群的总生存和无进展生存。
主要发现
- 两组最常见(任一组≥10%患者)治疗相关3级及以上不良事件为高血压(联合组95/429例[22%] vs 舒尼替尼组84/425例[20%])、丙氨酸氨基转移酶升高(54例[13%] vs 11例[3%])和腹泻(46例[11%] vs 23例[5%])。
- 自首次 interim 分析以来未报告新的治疗相关死亡。
临床怎么用
- 对未经治疗的晚期透明细胞肾细胞癌患者,可考虑帕博利珠单抗联合阿昔替尼作为一线治疗。
- 治疗期间需关注高血压、丙氨酸氨基转移酶升高和腹泻等治疗相关不良事件。
局限性
- 本研究为探索性扩展随访分析,主要终点已在首次 interim 分析达到,更新数据仅报告名义p值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The first interim analysis of the KEYNOTE-426 study showed superior efficacy of pembrolizumab plus axitinib over sunitinib monotherapy in treatment-naive, advanced renal cell carcinoma. The exploratory analysis with extended follow-up reported here aims to assess long-term efficacy and safety of pembrolizumab plus axitinib versus sunitinib monotherapy in patients with advanced renal cell carcinoma. METHODS: In the ongoing, randomised, open-label, phase 3 KEYNOTE-426 study, adults (≥18 years old) with treatment-naive, advanced renal cell carcinoma with clear cell histology were enrolled in 129 sites (hospitals and cancer centres) across 16 countries. Patients were randomly assigned (1:1) to receive 200 mg pembrolizumab intravenously every 3 weeks for up to 35 cycles plus 5 mg axitinib orally twice daily or 50 mg sunitinib monotherapy orally once daily for 4 weeks per 6-week cycle. Randomisation was done using an interactive voice response system or integrated web response system, and was stratified by International Metastatic Renal Cell Carcinoma Database Consortium risk status and geographical region. Primary endpoints were overall survival and progression-free survival in the intention-to-treat population. Since the primary endpoints were met at the first interim analysis, updated data are reported with nominal p values. This study is registered with ClinicalTrials.gov, NCT02853331. FINDINGS: Between Oct 24, 2016, and Jan 24, 2018, 861 patients were randomly assigned to receive pembrolizumab plus axitinib (n=432) or sunitinib monotherapy (n=429). With a median follow-up of 30·6 months (IQR 27·2-34·2), continued clinical benefit was observed with pembrolizumab plus axitinib over sunitinib in terms of overall survival (median not reached with pembrolizumab and axitinib vs 35·7 months [95% CI 33·3-not reached] with sunitinib); hazard ratio [HR] 0·68 [95% CI 0·55-0·85], p=0·0003) and progression-free survival (median 15·4 months [12·7-18·9] vs 11·1 months [9·1-12·5]; 0·71 [0·60-0·84], p<0·0001). The most frequent (≥10% patients in either group) treatment-related grade 3 or worse adverse events were hypertension (95 [22%] of 429 patients in the pembrolizumab plus axitinib group vs 84 [20%] of 425 patients in the sunitinib group), alanine aminotransferase increase (54 [13%] vs 11 [3%]), and diarrhoea (46 [11%] vs 23 [5%]). No new treatment-related deaths were reported since the first interim analysis. INTERPRETATION: With extended study follow-up, results from KEYNOTE-426 show that pembrolizumab plus axitinib continues to have superior clinical outcomes over sunitinib. These results continue to support the first-line treatment with pembrolizumab plus axitinib as the standard of care of advanced renal cell carcinoma. FUNDING: Merck Sharp & Dohme Corp, a subsidiary of Merck & Co, Inc.
引用
- Powles T, Plimack ER, Soulières D, et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial. Lancet Oncol. 2020. PMID: 33284113. doi:10.1016/S1470-2045(20)30436-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。